Author

admin

Browsing

From established players to up-and-coming firms, Canada’s pharmaceutical company landscape is diverse and dynamic.

Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well.

Read on to learn about what’s been driving the share prices of the best-performing Canadian pharma stocks.

1. Cipher Pharmaceuticals (TSX:CPH,OTC:CPHRF)

Year-over-year gain: 48.2 percent
Market cap: C$330.79 million
Share price: C$12.33

Cipher Pharmaceuticals is a specialty pharma company with a diverse portfolio of treatments, including a range of dermatology and acute hospital care products. The company has out-licensed some of its offerings as well. Cipher began trading on the OTCQX Best Market under the symbol CPHRF in early 2024.

In addition to its current portfolio, Cipher has acquired Canadian rights to CF-101, a dermatology treatment for moderate to severe plaque psoriasis is currently expected to undergo Phase III clinical trials. The company is also conducting proof-of-concept studies on DTR-001, a topical treatment for removing tattoos.

In 2024, Cipher announced it had signed a definitive asset purchase agreement with ParaPRO for its US-based Natroba operations and global product rights, and the news caused Cipher’s share price to spike significantly.

During its Q1 results reporting in May 2025, the company announced a US$15 million debt repayment.

2. HLS Therapeutics (TSX:HLS)

Year-over-year gain: 42.03 percent
Market cap: C$154.95 million
Share price: C$4.90

HLS Therapeutics focuses on drugs for cardiovascular and central nervous system problems, often through partnerships. The company specializes in acquiring and commercializing pharmaceuticals that address unmet needs. Key commercial products include Vascepa, Clozaril for treatment-resistant schizophrenia and cholesterol-lowering therapies NEXLETOL and NEXLIZET.

Additionally, the company generates revenue from a diversified portfolio of royalty interests on various products marketed by third parties.

3. Medexus Pharmaceuticals (TSX:MDP,OTC:MEDXF)

Year-over-year gain: 23.25 percent
Market cap: C$92.9 million
Share price: C$2.81

Medexus Pharmaceuticals specializes in bringing drugs to treat rare diseases to North America. The company manages the entire process through its fully integrated operations, from acquiring and developing drugs to marketing and selling them. Some of its key products include treatments for hemophilia B and rheumatoid arthritis, as well as a line of drugs for autoimmune diseases like lupus and allergy treatments.

In November 2024, Medexus Pharmaceuticals announced it had successfully negotiated with the pan-Canadian Pharmaceutical Alliance to make treosulfan, which Medexus commercialized in Canada under the name Trecondyv, available to publicly funded drug programs and patients. Trecondyv is indicated as part of conditioning treatment prior to bone marrow transplants in patients with certain types of blood cancers.

In addition to Canada, Medexus has the exclusive commercialization rights to treosulfan in the US, where it received approval from the US Food and Drug Administration (FDA) in January 2025.

4. Satellos Bioscience (TSXV:MSCL,OTC:MSCLF)

Year-over-year gain: 18 percent
Market cap: C$102.26 million
Share price: C$0.59

Satellos Bioscience is a Canadian pharmaceutical company expanding treatment options for muscle disorders. The company has focused specifically on Duchenne muscular dystrophy, developing therapies to regenerate and repair muscle tissue by targeting the specific biological pathways involved. Its lead candidate SAT-3247 targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.

The company began enrolment for a multiple-ascending-dose arm of the Phase 1 study for SAT-3247 last November after no drug-related adverse events were reported in the single-ascending-dose group.

In May of this year, Satellos announced results from its Phase 1b trial, reporting SAT-3247 has shown positive safety and pharmacokinetic data and encouraging early functional results, clearing the path for a planned Phase 2 trial.

5. NurExone Biologic (TSXV:NRX,OTC:NRXBF)

Year-over-year gain: 1.41 percent
Market cap: C$44.18 million
Share price: C$0.72

NurExone Biologic is the biopharmaceutical company behind ExoTherapy, a drug delivery platform that uses exosomes, which are nano-sized extracellular vesicles, to create treatments for central nervous system disorders, spinal cord injuries and traumatic brain injuries. It is a less invasive alternative to cell transplantation, which requires surgery and carries the risk of rejection.

NurExone’s first nano-drug, ExoPTEN, uses a proprietary sIRNA sequence delivered with the ExoTherapy platform to treat spinal cord injuries. ExoPTEN received orphan drug designation from the US Food and Drug Administration (FDA) in October 2023, meaning it has been recognized as a potential treatment for rare medical conditions. The designation makes it eligible for incentives such as market exclusivity and regulatory assistance aimed at accelerating its development and approval.

The company released preclinical results from animal testing evaluating the efficacy of its nano-drug ExoPTEN in restoring lost vision at the end of 2024. In July 2025, preclinical studies indicated that ExoPTEN could improve walking quality in patients with spinal cord injuries.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

After spiraling from crisis to crisis over much of the past seven years, Boeing is stabilizing under CEO Kelly Ortberg’s leadership.

Ortberg, a longtime aerospace executive and an engineer whom the manufacturer plucked from retirement to fix the problem-addled company last year, is set this week to outline significant progress since he took the helm a year ago. Boeing reports quarterly results and gives its outlook on Tuesday.

So far, investors are liking what they’ve been seeing. Shares of the company are up more than 30% so far this year.

Wall Street analysts expect the aircraft manufacturer to halve its second-quarter losses from a year ago when it reports. Ortberg told investors in May that the manufacturer expects to generate cash in the second half of the year. Boeing’s aircraft production has increased, and its airplane deliveries just hit the highest level in 18 months.

It’s a shift for Boeing, whose successive leaders missed targets on aircraft delivery schedules, certifications, financial goals and culture changes that frustrated investors and customers alike, while rival Airbus pulled ahead.

“The general agreement is that the culture is changing after decades of self-inflicted knife wounds,” said Richard Aboulafia, managing director at AeroDynamic Advisory, an aerospace consulting firm.

Analysts expect the company to post its first annual profit since 2018 next year.

“When he got the job, I was not anywhere as near as optimistic as today,” said Douglas Harned, senior aerospace and defense analyst at Bernstein.

Ortberg’s work was already cut out for him, but the challenges multiplied when he arrived.

As the company hemorrhaged cash, Ortberg announced massive cost cuts, including laying off 10% of the company. Its machinists who make the majority of its airplanes went on strike for seven weeks until the company and the workers’ union signed a new labor deal. Ortberg also oversaw a more than $20 billion capital raise last fall, replaced the head of the defense unit and sold off its Jeppesen navigation business.

Ortberg bought a house in the Seattle area, where Boeing makes most of its planes, shortly after taking the job last August, and his presence has been positive, aerospace analysts have said.

“He’s showing up,” Aboulafia said. “You show up, you talk to people.”

Boeing declined to make Ortberg available for an interview.

Boeing’s leaders hoped for a turnaround year in 2024. But five days in, a door-plug blew out of a nearly new Boeing 737 Max 9 as it climbed out of Portland. The almost-catastrophe brought Boeing a production slowdown, renewed Federal Aviation Administration scrutiny and billions in cash burn.

Key bolts were left off the plane before it was delivered to Alaska Airlines. It was the latest in a series of quality problems at Boeing, where other defects have required time-consuming reworking.

Boeing had already been reeling from two deadly Max crashes in 2018 and 2019 that sullied the reputation of America’s largest exporter. The company in May reached an agreement with the Justice Department to avoid prosecution stemming from a battle over a previous criminal conspiracy charge tied to the crashes. Victims’ family members slammed the deal when it was announced.

For years, executives at top Boeing airline customers complained publicly about the manufacturer and its leadership as they grappled with delays. Ryanair CEO Michael O’Leary told investors in May 2022 that management needed a “reboot or boot up the arse.”

Last week, O’Leary had a different tune.

“I continue to believe Kelly Ortberg, [and Boeing Commercial Airplane unit CEO] Stephanie Pope are doing a great job,” he said on an earnings call. “I mean, there is no doubt that the quality of what is being produced, the hulls in Wichita and the aircraft in Seattle has dramatically improved.”

United Airlines CEO Scott Kirby cast doubt over the Boeing 737 Max 10 after the January 2024 door-plug accident, as the carrier prepared not to have that aircraft in its fleet plan. The plane is still not certified, but Kirby has said Boeing has been more predictability on airplane deliveries.

Still, delays for the Max 10, the largest of the Max family, and the yet-to-be certified Max 7, the smallest, are a headache for customers, especially since having too few or too many seats on a flight can determine profitability for airlines.

“They’re working the right problems. The consistency of deliveries is much better,” Southwest Airlines CEO Bob Jordan said in an interview last month. “But there’s no update on the Max 7. We’re assuming we are not flying it in 2026.”

Boeing under Ortberg still has much to fix.

The FAA capped Boeing’s production at 38 Maxes a month, a rate that it has reached. To go beyond that, to a target of 42, Boeing will need the FAA’s blessing.

Ortberg said this year that the company is stabilizing to go beyond that rate. Manufacturers get paid when aircraft are delivered, so higher production is key.

“I would suspect they would be having those discussions very soon,” Harned said. “It’s 47 [a month] that I think is the challenging break.”

He added that Boeing has a lot of inventory on hand to help increase production.

Its defense unit has also suffered. The defense unit encompasses programs like the KC-46 tanker program and Air Force One, which has drawn public ire from President Donald Trump. Trump, frustrated with delays on the two new jets meant to serve the president, turned to a used Qatari Boeing 747 to potentially use as a presidential aircraft, though insiders say that used plane could require months of reoutfitting.

Ortberg replaced the head of that unit last fall.

A strike could also be on the horizon at the defense unit after factory workers “overwhelmingly” rejected a new labor deal, according to their union, the International Association of Machinists and Aerospace Workers Local 837.

“The proposal from Boeing Defense fell short of addressing the priorities and sacrifices of the skilled IAM Union workforce,” the union said Sunday. “Our members are standing together to demand a contract that respects their work and ensures a secure future.”

There is a seven-day cooling off period before a strike would begin, if a new deal isn’t reached.

“They’re not totally out of the woods,” Harned said.

Boeing and Ortberg also need to start thinking about a new jet, some industry members said. Its best-selling 737 first debuted in 1967, and the company was looking at a midsize jetliner before the two crashes sent its attention elsewhere.

“Already there’s been a reversal from ‘read my lips, no new jet.’ I would like to see that accelerate,” Aboulafia said. “He is the guy to make that happen.”

This post appeared first on NBC NEWS

The Senate confirmed President Donald Trump’s pick to lead the Centers for Disease Control and Prevention after his first choice struggled to gain support.

Susan Monarez, a longtime fixture in Washington who has taken on leadership positions in a number of government public health roles, was confirmed by the Senate on Tuesday, crossing yet another position off the lengthy and growing number of nominees awaiting confirmation.

Monarez was confirmed on a 51to 47party line vote.

Across her roughly two-decade career in D.C., she has served as deputy director of the Advanced Research Projects Agency for Health within the Department of Health and Human Services and in roles at the White House, including at the Office of Science and Technology Policy and the National Security Council.

She is the first CDC director to undergo the Senate confirmation process after a new law changed the requirement in 2023. Prior to her confirmation, Monarez had served as the acting director of the CDC since the beginning of this year.

But Monarez, who has a Ph.D. in microbiology and immunology, was not Trump’s first pick to lead the public health agency, which is tasked with protecting Americans from public health threats.

Trump tapped Monarez in March shortly after withdrawing his nomination of Dr. David Weldon, a former House member, after it was clear that he couldn’t get enough votes from Senate Republicans to make it across the finish line.

He lauded Monarez’s credentials, and charged that Americans had ‘lost confidence’ in the CDC.

‘Dr. Monarez will work closely with our GREAT Secretary of Health and Human Services, Robert Kennedy Jr,’ he said on social media at the time. ‘Together, they will prioritize Accountability, High Standards, and Disease Prevention to finally address the Chronic Disease Epidemic and, MAKE AMERICA HEALTHY AGAIN!’

But questions also linger on how well Monarez and Health and Human Services Secretary Robert F. Kennedy Jr. might work together.

During her confirmation hearing last month, Senate Democrats grilled Monarez over whether she agreed with Kennedy’s positions on vaccines. Kennedy has long been outspoken about his skepticism regarding vaccines, particularly COVID-19 vaccines.

The CDC has been hit with thousands of staff cuts and resignations and subject to changes in vaccine policy — notably Kennedy’s decision to remove the COVID-19 from the vaccine schedule for pregnant women and healthy children — in the last six months. 

‘I think vaccines save lives. I think that we need to continue to support the promotion of utilization of vaccines,’ Monarez said during her confirmation hearing.

Her confirmation also comes as Kennedy, in his budget request for the HHS, seeks a slash in funding to the CDC of nearly 50%, or from about $9.2 billion to $4.2 billion, for the upcoming fiscal year.

But Kennedy made clear in an X post at the time of her nomination that he supports Monarez to take on the position.

‘I handpicked Susan for this job because she is a longtime champion of MAHA values, and a caring, compassionate and brilliant microbiologist and a tech wizard who will reorient CDC toward public health and gold-standard science,’ he said. ‘I’m so grateful to President Trump for making this appointment.’

And an HHS spokesperson told Fox News Digital, ‘Once Dr. Monarez is confirmed, the Secretary looks forward to working with her to advance common-sense policies that will Make America Healthy Again.’

This post appeared first on FOX NEWS

European stock markets are poised for a higher open on Tuesday, with major bourses looking to shake off the previous session’s losses.

A wave of strong corporate earnings reports, notably from British bank Barclays and pharmaceutical giant AstraZeneca, is providing a positive catalyst for the market, even as investors continue to seek clarity on the details of the recent US-EU framework trade deal.

Futures data from IG suggests a positive start for European markets, with major bourses like London’s FTSE 100 and Germany’s DAX expected to open around 0.2% higher.

This comes after an initial burst of optimism on Monday over the US-EU trade deal faded by the end of the session, ultimately leaving the pan-European Stoxx 600 index with a 0.23% loss.

Investors will continue to hunt for any new details on the trade outlook today, as uncertainty remains for key sectors including pharmaceuticals and products like spirits, which were not explicitly covered in the initial framework.

Some analysts believe the recent positive trade news has largely run its course for now. “We see the tentative trade deal with the EU as pretty much completing the run of good trade news that has lifted global confidence and equity markets, and weakened the [US dollar],” Standard Chartered macro strategist Steve Englander said in a Monday note.

He added, “The deals are a negative from a global growth perspective but appear to be something that US trading partners can live with.”

Corporate stars shine: AstraZeneca and Barclays beat expectations

Tuesday is a busy day for corporate earnings, with several major companies reporting ahead of the bell, offering a more fundamental focus for investors.

  • AstraZeneca: The Anglo-Swedish pharmaceutical firm posted better-than-expected second-quarter earnings, driven by strong demand for its key cancer and biopharmaceutical products.

    AstraZeneca reported revenues of $14.46 billion for the three-month period ending June 30, a figure that came in ahead of the $14.07 billion estimated by analysts in an LSEG poll. Quarterly adjusted core operating profit also beat forecasts, coming in at $4.58 billion versus the $4.48 billion anticipated.

    The FTSE 100 company maintained its full-year forecast for revenues to rise by a high single-digit percentage, despite geopolitical challenges, and reiterated its ambitions to grow its US footprint to deliver $80 billion in revenue by 2030.

    Last week, AstraZeneca had announced plans to invest $50 billion in bolstering its US manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to ramp up its stateside spending in the wake of US trade tariffs.

  • Barclays: British bank Barclays also delivered a strong performance, beating profit expectations and announcing a new £1 billion ($1.33 billion) share buyback program.

    The bank reported a pre−tax profit of £2.5 billion ($ 3.34 billion) for the second quarter, comfortably surpassing the mean LSEG forecast of £2.23 billion. Group revenues met analyst projections of £7.2 billion. The bank noted that market volatility had helped to boost its investment banking revenues during the quarter.

A host of other earnings reports are also due today from European giants like L’Oréal and Ferrovial, as well as major US companies including Boeing, Starbucks, Visa, and PayPal, which will be closely watched for their global outlook.

The post Europe markets open: FTSE, DAX futures up 0.2% on strong Barclays, AstraZeneca earnings appeared first on Invezz

Samsung Electronics has entered into a $16.5 billion contract for supplying semiconductors to Tesla, based on a regulatory filing by the South Korean firm and Tesla CEO Elon Musk’s posts on X.

The memory chipmaker, which had not named the counterparty, mentioned in its filing that the effective start date of the contract was July 26, 2025 — receipt of orders — and its end date was Dec. 31, 2033.

However, Musk later confirmed in a reply to a post on social media platform X that Tesla was the counterparty.

He also posted: “Samsung’s giant new Texas fab will be dedicated to making Tesla’s next-generation AI6 chip. The strategic importance of this is hard to overstate. Samsung currently makes AI4.TSMC will make AI5, which just finished design, initially in Taiwan and then Arizona.”

“Samsung agreed to allow Tesla to assist in maximizing manufacturing efficiency. This is a critical point, as I will walk the line personally to accelerate the pace of progress,” Musk said on X, and suggested that the deal with Samsung could likely be even larger than the announced $16.5 billion.

Samsung earlier said that details of the deal, including the name of the counterparty, will not be disclosed until the end of 2033, citing a request from the second party “to protect trade secrets,” according to a Google translation of the filing in Korean on Monday.

“Since the main contents of the contract have not been disclosed due to the need to maintain business confidentiality, investors are advised to invest carefully considering the possibility of changes or termination of the contract,” the company said.

The company’s shares rose over 6% in trading on Monday to reach their highest level since September 2024.

Tesla was a probable customer, Ray Wang, research director of semiconductors, supply chain and emerging technology at The Futurum Group, told CNBC before Musk’s post. Bloomberg News had earlier reported that Samsung’s deal was with Tesla, citing a source.

Samsung’s foundry service manufactures chips based on designs provided by other companies. It is the second largest provider of foundry services globally, behind Taiwan Semiconductor Manufacturing Company.

The company stated in April that it aimed to commence 2 nanometer mass production in its foundry business and secure major orders for the next-generation technology. In semiconductor technology, smaller nanometer sizes signify more compact transistor designs, which lead to greater processing power and efficiency.

Local South Korean media outlets have also reported that American chip firm Qualcomm could place an order for chips manufactured using Samsung’s 2 nanometer technology.

Samsung, which is set to deliver earnings on Thursday, expects its second-quarter profit to more than halve. An analyst previously told CNBC that the disappointing forecast was due to weak orders for its foundry business and as the company has struggled to capture AI demand for its memory business.

The company has fallen behind competitors SK Hynix and Micron in high-bandwidth memory chips — an advanced type of memory used in AI chipsets.

SK Hynix, the leader in HBM, has become the main supplier of these chips to American AI behemoth Nvidia. While Samsung has reportedly been working to get the latest version of its HBM chips certified by Nvidia, a report from a local outlet suggests these plans have been pushed back to at least September.

This post appeared first on NBC NEWS

President Donald Trump’s new deadline for Russia to end the conflict with Ukraine is an additional ‘step towards war,’ according to former Russian President Dmitry Medvedev.  

Medvedev, now the deputy chairman of the Security Council of Russia, cautioned that Trump’s announcement Monday that Russia must end the conflict with Ukraine in 10 to 12 days would not end well for the U.S. 

‘Trump’s playing the ultimatum game with Russia: 50 days or 10… He should remember 2 things: 1. Russia isn’t Israel or even Iran. 2. Each new ultimatum is a threat and a step towards war. Not between Russia and Ukraine, but with his own country,’ Medvedev said in a post on X on Monday. ‘Don’t go down the Sleepy Joe road!’

While Trump announced on July 14 that he would sign off on ‘severe tariffs’ against Russia if Moscow failed to agree to a peace deal within 50 days, Trump said Monday that waiting that period of time was futile amid stalled negotiations. 

‘I’m going to make a new deadline, of about 10 — 10 or 12 days from today,’ Trump told reporters from Scotland. ‘There’s no reason for waiting. It was 50 days. I wanted to be generous, but we just don’t see any progress being made.’

Trump’s remarks come as his frustration with Putin has grown in recent weeks amid no progress toward peace between Russia and Ukraine, and just a day after Russia launched more than 300 drones, four cruise missiles and three ballistic missiles into Ukraine, according to the Ukrainian air force.

 

Trump called out Putin for providing lip service during their discussions while not taking proactive steps to end the war. As a result, Trump said he’s grown ‘disappointed’ in the Russian leader and that he’s ‘not so interested in talking anymore’ with Putin. 

‘He talks — we have such nice conversations, such respectful and nice conversation. And then, people die the following night,’ Trump said Monday. 

Following Trump’s announcement about whittling down the deadline for a peace deal, Ukrainian President Volodymyr Zelenskyy thanked Trump for his ‘clear stance and expressed determination’ to resolve the conflict.

‘I thank President Trump for his focus on saving lives and stopping this horrible war,’ Zelenskyy said in a post on X on Monday. ‘Ukraine remains committed to peace and will work tirelessly with the U.S. to make both our countries safer, stronger, and more prosperous.’

Zelenskyy previously came under scrutiny from Vice President JD Vance in February during an Oval Office meeting for not voicing more gratitude for U.S. support for Kyiv as it battles Moscow.

Although Trump has historically boasted about having a solid relationship with Putin, he has publicly voiced increased frustration with Putin in recent weeks as the war rages on between Russia and Ukraine. 

‘We get a lot of bulls— thrown at us by Putin, if you want to know the truth,’ Trump said during a Cabinet meeting on July 8. ‘He’s very nice to us all the time, but it turns out to be meaningless.’

Fox News Digital’s Caitlin McFall contributed to this report.

This post appeared first on FOX NEWS

The United States and the European Union announced on Sunday a broad framework for a new trade agreement aimed at defusing tensions between the two economic giants and preventing what could have become a damaging transatlantic trade war.

The deal imposes a uniform 15% tariff on most goods exported from the EU to the United States, including automobiles and pharmaceuticals.

Though the rate is higher than the 10% cap the European bloc had hoped for, it is significantly lower than the 30% tariffs that President Donald Trump had previously threatened.

Flanked by Ursula von der Leyen, President of the European Commission, Trump said the agreement would usher in a new era of “balanced, tough, and fair trade” between the two long-standing allies.

“We made it,” he said, calling the outcome “the biggest of all the deals.”

EU to purchase $750 bn worth of American energy, increase investment in the US

Central to the agreement are substantial pledges from the European Union on energy and investment.

Von der Leyen confirmed that the bloc would purchase $750 billion worth of American energy over the next three years.

Trump also announced that EU member states had agreed to increase their total investment in the US economy by over $600 billion.

This investment, officials said, would span key industries, including automotive manufacturing, pharmaceuticals, and defense.

The EU has also committed to purchasing an unspecified amount of American military equipment.

“It’s a good deal, it’s a huge deal,” von der Leyen said, calling the negotiations “tough” but ultimately fruitful.

Some relief was offered on select goods.

Both sides agreed to reduce tariffs to zero on aircraft, aircraft parts, some agricultural products, semiconductor equipment, generic medicines, and certain chemicals—signaling a degree of cooperation that had been lacking in recent years.

Steel and pharmaceuticals excluded from the deal

Despite these developments, not all sectors emerged unscathed.

One conspicuous exclusion from the deal is the steep 50% tariff the Trump administration had earlier imposed globally on steel and aluminum imports.

While von der Leyen hinted that these may be addressed in follow-up negotiations, no immediate relief was offered.

Pharmaceuticals—Europe’s most significant export category to the United States—also remain outside the current agreement and will still be subject to a 15% tariff.

Von der Leyen acknowledged that the pharmaceutical issue had been “placed on a separate sheet of paper,” indicating that further negotiations are expected.

A senior U.S. official clarified that pharmaceutical and semiconductor exports from Europe would continue to face the 15% tariff rate regardless of potential global tariff policies under review by the Trump administration.

Those measures, which could be announced in the coming weeks, are part of a broader strategy to recalibrate US trade policy across critical supply chains.

Mixed reactions from Europe highlight unease

Reactions across the European continent were mixed. German Chancellor Friedrich Merz welcomed the accord, praising it as a means of avoiding “an unnecessary escalation in transatlantic trade relations.”

He noted, however, that deeper tariff reductions would have been preferable.

“We were able to preserve our core interests,” Merz said, while expressing disappointment over the limited scope of concessions.

Business groups were more critical. Wolfgang Niedermark of the Federation of German Industries warned that even the 15% rate would have “immense negative effects” on Germany’s export-driven manufacturing sector.

In France, concerns were more pointed.

“The agreement negotiated by the European Commission with the United States will bring temporary stability to economic actors threatened by the escalation of American tariffs, but it is unbalanced,” said French European Affairs Minister Benjamin Haddad on X, the social media platform formerly known as Twitter.

Industry Minister Marc Ferracci echoed the sentiment, adding that more detailed discussions—potentially stretching over weeks or even months—would be needed before a binding legal agreement could be finalized.

A temporary shield against global economic volatility

Though the announced deal appears to stave off immediate retaliation and avoids an all-out tariff war, trade experts cautioned against celebrating too early.

Mujtaba Rahman of the Eurasia Group noted that several critical areas remain ambiguous.

“If there aren’t further exemptions to be negotiated to that 15%, I think it’s a far more suboptimal deal than the member states were hoping to achieve,” he said.

The agreement does mirror recent trade pacts with other US partners.

The 15% rate is identical to what was agreed upon with Japan last week and is more favourable than the 19 to 20% tariffs recently slapped on Southeast Asian nations.

However, it remains higher than the 10% rate applied to the UK.

Carsten Brzeski, global head of macroeconomics at ING, offered cautious optimism.

“At face value, today’s agreement would clearly bring an end to the uncertainty of recent months,” he said.

“An escalation of the U.S.-EU trade tensions would have been a severe risk for the global economy. This risk seems to have been avoided.”

For now, though, leaders on both sides were keen to signal progress.

“This deal enables trade, it rebalances our relationship,” von der Leyen said. Whether it holds under pressure remains to be seen.

The post EU-US trade deal: 15% tariff, $750B energy purchase — but pharma, steel excluded appeared first on Invezz

President Donald Trump blasted the European Union for not providing aid to Gaza on Sunday, adding that Israel must ‘make a decision’ about how to handle the region with Hamas still holding hostages.

Trump made the comments while meeting with European Commission President Ursula von der Leyen in Scotland. He said that the U.S. has given millions in aid to Gazans, but claimed there has been no assistance from European countries.

‘We gave $60 million two weeks ago for food for Gaza, and nobody acknowledged it. Nobody talks about it. And it makes you feel a little bad when you do that. And, you know, you have other countries not giving anything. None of the European countries, by the way, gave – I mean, nobody gave but us and nobody said, gee, thank you very much. And it would be nice to have at least a thank you.’

Trump went on to note that a deal needs to be made between Israel and Hamas to end the war and return the last remaining hostages to Israel, despite many of them being dead.

‘But we have a lot of bodies, and the parents want those bodies as much as they would want their child if that child were alive,’ Trump said of the hostages and their families.

He suggested that Hamas is reluctant to make a deal for the final hostages because they feel it would be ‘the end for them’ if they lose leverage against Israel.

‘You know, they had a routine discussion the other day and all of a sudden they hardened up. They don’t want to give them back. And so Israel is going to have to make a decision,’ Trump said.

The meeting comes as the IDF highlighted its efforts to deliver aid into Gaza after restricting the flow in recent months.

Israel is now conducting airdrops for aid throughout the region, and the IDF says it conducted 28 drops in a matter of hours on Sunday.

‘Let me be clear: Israel supports aid for civilians, not for Hamas. The IDF will continue to support the flow of humanitarian aid to the people of Gaza,’ an IDF spokesperson said, claiming Israel transferred roughly 250 trucks full of aid into Gaza this week.

The IDF argues the reports about starvation in Gaza were a false campaign promoted by Hamas, but hunger is spreading across the region after the United Nations and the IDF previously failed to reach an agreement about aid distribution, Fox News’ Trey Yingst reported. 

This post appeared first on FOX NEWS